Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

About this update from Novocure Limited

[{"type":"text","content":"\nQuarterly net revenues of $144.0 million, representing 45 percent growth versus the fourth quarter 2019 and 9 percent growth versus the third quarter 2020\n\nQuarterly net income of $4.9 million with $0.05 in earnings per share\n\n ST. HELIER, Jersey--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical and product development programs. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields.\n\n\n\nFourth quarter 2020 highlights include:\n\n\n\n\n\n \n\n\n\nThree Months Ended\nDecember 31,\n\n\n\n \n\n\n\nTwelve Months Ended\nDecember 31,\n\n\n\n\n\n \n\n\n\n2020\n\n\n\n \n\n\n\n2019\n\n\n\n \n\n\n\n% Change\n\n\n\n \n\n\n\n2020\n\n\n\n \n\n\n\n2019\n\n\n\n \n\n\n\n% Change\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nFinancial, in millions\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nNet revenues\n\n\n\n$\n\n\n\n144.0\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n99.2\n\n\n\n \n\n\n\n \n\n\n\n45\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n494.4\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n351.3\n\n\n\n \n\n\n\n \n\n\n\n41\n\n\n\n%\n\n\n\n\n\nGross Profit\n\n\n\n$\n\n\n\n115.8\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n74.4\n\n\n\n \n\n\n\n \n\n\n\n56\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n387.9\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n262.7\n\n\n\n \n\n\n\n \n\n\n\n48\n\n\n\n%\n\n\n\n\n\nNet income (loss)\n\n\n\n$\n\n\n\n4.9\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n4.3\n\n\n\n \n\n\n\n \n\n\n\n15\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n19.8\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n(7.2)\n\n\n\n \n\n\n\n \n\n\n\n(374)\n\n\n\n%\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nAdjusted EBITDA(1)\n\n\n\n$\n\n\n\n34.8\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n17.3\n\n\n\n \n\n\n\n \n\n\n\n101\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n115.3\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n60.0\n\n\n\n \n\n\n\n \n\n\n\n92\n\n\n\n%\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\...

More updates from Novocure Limited